Seminars in Fetal & Neonatal Medicine
Volume 12, Issue 4 , Pages 250-258 , August 2007

Epo and other hematopoietic factors

  • Sandra Juul

      Affiliations

    • Department of Pediatrics, Division of Neonatology, Health Sciences Building, University of Washington, Box 356320, Seattle, WA 98195, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 206 221 6814; fax: +1 206 543 8926.
    • ,
  • Ursula Felderhoff-Mueser

      Affiliations

    • Department of Neonatology, Universitätsmedizin Berlin, Berlin, Germany

References 

  1. Nicola NA. Cytokine pleiotropy and redundancy: a view from the receptor. Stem Cells. 1994;12(Suppl. 1):3–12[discussion 12–14]
  2. Schneider A, Kuhn HG, Schabitz WR. A role for g-csf (granulocyte-colony stimulating factor) in the central nervous system. Cell Cycle. 2005;4:1753–1757
  3. Juul S. Recombinant erythropoietin as a neuroprotective treatment: in vitro and in vivo models. Clin Perinatol. 2004;31:129–142
  4. Konishi Y, Chui DH, Hirose H, Kunishita T, Tabira T. Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. Brain Res. 1993;609:29–35
  5. Masuda S, Nagao M, Takahata K, Konishi Y, Gallyas F, Tabira T, et al. Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem. 1993;268:11208–11216
  6. Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell. 1995;83:59–67
  7. Widness JA, Schmidt RL, Sawyer ST. Erythropoietin transplacental passage – review of animal studies. J Perinat Med. 1995;23:61–70
  8. Ohneda O, Yanai N, Obinata M. Erythropoietin as a mitogen for fetal liver stromal cells which support erythropoiesis. Exp Cell Res. 1993;208:327–331
  9. Morakkabati N, Gollnick F, Meyer R, Fandrey J, Jelkmann W. Erythropoietin induces Ca2+ mobilization and contraction in rat mesangial and aortic smooth muscle cultures. Exp Hematol. 1996;24:392–397
  10. Wu H, Lee SH, Gao J, Liu X, Iruela-Arispe ML. Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development. 1999;126:3597–3605
  11. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood. 1999;93:2627–2636
  12. Juul SE, Joyce AE, Zhao Y, Ledbetter DJ. Why is erythropoietin present in human milk? Studies of erythropoietin receptors on enterocytes of human and rat neonates. Pediatr Res. 1999;46:263–268
  13. Juul SE, Yachnis AT, Christensen RD. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev. 1998;52:235–249
  14. Sawyer ST, Krantz SB, Sawada K. Receptors for erythropoietin in mouse and human erythroid cells and placenta. Blood. 1989;74:103–109
  15. Mioni R, Gottardello F, Bordon P, Montini G, Foresta C. Evidence for specific binding and stimulatory effects of recombinant human erythropoietin on isolated adult rat leydig cells. Acta Endocrinol (Copenh). 1992;127:459–465
  16. Tabira T, Konishi Y, Gallyas F. Neurotrophic effect of hematopoietic cytokines on cholinergic and other neurons in vitro. Int J Dev Neurosci. 1995;13:241–252
  17. Juul SE, Yachnis AT, Rojiani AM, Christensen RD. Immunohistochemical localization of erythropoietin and its receptor in the developing human brain. Pediatr Dev Pathol. 1999;2:148–158
  18. Iguchi T, Sogo S, Hisha H, Taketani S, Adachi Y, Miyazaki R, et al. Hgf activates signal transduction from epo receptor on human cord blood cd34+/cd45+ cells. Stem Cells. 1999;17:82–91
  19. Akahane K, Tojo A, Urabe A, Takaku F. Pure erythropoietic colony and burst formations in serum-free culture and their enhancement by insulin-like growth factor 1. Exp Hematol. 1987;15:797–802
  20. Buescher U, Hertwig K, Wolf C, Dudenhausen JW. Erythropoietin in amniotic fluid as a marker of chronic fetal hypoxia. Int J Gynaecol Obstet. 1998;60:257–263
  21. Stangenberg M, Legarth J, Cao HL, Lingman G, Persson B, Rahman F, et al. Erythropoietin concentrations in amniotic fluid and umbilical venous blood from Rh-immunized pregnancies. J Perinat Med. 1993;21:225–234
  22. Ohls RK, Harcum J, Li Y, Davila G, Christensen RD. Serum erythropoietin concentrations fail to increase after significant phlebotomy losses in ill preterm infants. J Perinatol. 1997;17:465–467
  23. Rhondeau SM, Christensen RD, Ross MP, Rothstein G, Simmons MA. Responsiveness to recombinant human erythropoietin of marrow erythroid progenitors from infants with the “Anemia of prematurity”. J Pediatr. 1988;112:935–940
  24. Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2006;3:[CD004863]
  25. Aher S, Ohlsson A. Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2006;3:[CD004868]
  26. Garcia MG, Hutson AD, Christensen RD. Effect of recombinant erythropoietin on “Late” Transfusions in the neonatal intensive care unit: a meta-analysis. J Perinatol. 2002;22:108–111
  27. Pollak A, Hayde M, Hayn M, Herkner K, Lombard KA, Lubec G, et al. Effect of intravenous iron supplementation on erythropoiesis in erythropoietin-treated premature infants. Pediatrics. 2001;107:78–85
  28. Haiden N, Klebermass K, Cardona F, Schwindt J, Berger A, Kohlhauser-Vollmuth C, et al. A randomized, controlled trial of the effects of adding vitamin b12 and folate to erythropoietin for the treatment of anemia of prematurity. Pediatrics. 2006;118:180–188
  29. Ohls RK, Dai A. Long-acting erythropoietin: clinical studies and potential uses in neonates. Clin Perinatol. 2004;31:77–89
  30. Masuda S, Okano M, Yamagishi K, Nagao M, Ueda M, Sasaki R. A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem. 1994;269:19488–19493
  31. Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci. 2005;6:484–494
  32. Coleman T, Brines M. Science review: recombinant human erythropoietin in critical illness: a role beyond anemia?. Crit Care. 2004;8:337–341
  33. Ozer EA, Kumral A, Ozer E, Yilmaz O, Duman N, Ozkal S, et al. Effects of erythropoietin on hyperoxic lung injury in neonatal rats. Pediatr Res. 2005;58:38–41
  34. Juul SE, McPherson RJ, Farrell FX, Jolliffe L, Ness DJ, Gleason CA. Erytropoietin concentrations in cerebrospinal fluid of non-human primates and fetal sheep following high-dose recombinant erythropoietin. Biol Neonate. 2004;85:138–144
  35. Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, MacKenzie ET, et al. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab. 1999;19:643–651
  36. Siren AL, Knerlich F, Poser W, Gleiter CH, Bruck W, Ehrenreich H. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol (Berl). 2001;101:271–276
  37. Juul SE, Stallings SA, Christensen RD. Erythropoietin in the cerebrospinal fluid of neonates who sustained CNS injury. Pediatr Res. 1999;46:543–547
  38. Juul SE, Anderson DK, Li Y, Christensen RD. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res. 1998;43:40–49
  39. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science. 2004;305:239–242
  40. Wang X, Zhu C, Wang X, Gerwien JG, Schrattenholz A, Sandberg M, et al. The non-erythropoietic asialoerythropoietin protects against neonatal hypoxia-ischemia as potently as erythropoietin. J Neurochem. 2004;91:900–910
  41. Yu X, Lin CS, Costantini F, Noguchi CT. The human erythropoietin receptor gene rescues erythropoiesis and developmental defects in the erythropoietin receptor null mouse. Blood. 2001;98:475–477
  42. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between jak2 and nf-kappaB signalling cascades. Nature. 2001;412:641–647
  43. Chong ZZ, Kang JQ, Maiese K. Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J Cereb Blood Flow Metab. 2002;22:503–514
  44. Sola A, Rogido M, Lee BH, Genetta T, Wen TC. Erythropoietin after focal cerebral ischemia activates the Janus kinase-signal transducer and activator of transcription signaling pathway and improves brain injury in postnatal day 7 rats. Pediatr Res. 2005;57:481–487
  45. Matsushita H, Johnston MV, Lange MS, Wilson MA. Protective effect of erythropoietin in neonatal hypoxic ischemia in mice. Neuroreport. 2003;14:1757–1761
  46. Kumral A, Genc S, Ozer E, Yilmaz O, Gokmen N, Koroglu TF, et al. Erythropoietin downregulates bax and dp5 proapoptotic gene expression in neonatal hypoxic-ischemic brain injury. Biol Neonate. 2006;89:205–210
  47. Sun Y, Zhou C, Polk P, Nanda A, Zhang JH. Mechanisms of erythropoietin-induced brain protection in neonatal hypoxia-ischemia rat model. J Cereb Blood Flow Metab. 2004;24:259–270
  48. Spandou E, Soubasi V, Papoutsopoulou S, Karkavelas G, Simeonidou C, Kaiki-Astara A, et al. Erythropoietin prevents hypoxia/ischemia-induced DNA fragmentation in an experimental model of perinatal asphyxia. Neurosci Lett. 2004;366:24–28
  49. Sun Y, Calvert JW, Zhang JH. Neonatal hypoxia/ischemia is associated with decreased inflammatory mediators after erythropoietin administration. Stroke. 2005;36:1672–1678
  50. Keller M, Yang J, Griesmaier E, Gorna A, Sarkozy G, Urbanek M, et al. Erythropoietin is neuroprotective against nmda-receptor-mediated excitotoxic brain injury in newborn mice. Neurobiol Dis. 2006;24:357–366
  51. Kawakami M, Iwasaki S, Sato K, Takahashi M. Erythropoietin inhibits calcium-induced neurotransmitter release from clonal neuronal cells. Biochem Biophys Res Commun. 2000;279:293–297
  52. Tsai PT, Ohab JJ, Kertesz N, Groszer M, Matter C, Gao J, et al. A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J Neurosci. 2006;26:1269–1274
  53. Wang L, Zhang Z, Wang Y, Zhang R, Chopp M. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke. 2004;35:1732–1737
  54. Chang YS, Mu D, Wendland M, Sheldon RA, Vexler ZS, McQuillen PS, et al. Erythropoietin improves functional and histological outcome in neonatal stroke. Pediatr Res. 2005;58:106–111
  55. Demers EJ, McPherson RJ, Juul SE. Erythropoietin protects dopaminergic neurons and improves neurobehavioral outcomes in juvenile rats after neonatal hypoxia-ischemia. Pediatr Res. 2005;58:297–301
  56. Wei L, Han BH, Li Y, Keogh CL, Holtzman DM, Yu SP. Cell death mechanism and protective effect of erythropoietin after focal ischemia in the whisker-barrel cortex of neonatal rats. J Pharmacol Exp Ther. 2006;317:109–116
  57. Um M, Lodish HF. Antiapoptotic effects of erythropoietin in differentiated neuroblastoma sh-sy5y cells require activation of both the stat5 and akt signaling pathways. J Biol Chem. 2006;281:5648–5656
  58. Dzietko M, Felderhoff-Mueser U, Sifringer M, Krutz B, Bittigau P, Thor F, et al. Erythropoietin protects the developing brain against N-methyl-d-aspartate receptor antagonist neurotoxicity. Neurobiol Dis. 2004;15:177–187
  59. Solaroglu I, Solaroglu A, Kaptanoglu E, Dede S, Haberal A, Beskonakli E, et al. Erythropoietin prevents ischemia-reperfusion from inducing oxidative damage in fetal rat brain. Childs Nerv Syst. 2003;19:19–22
  60. Kumral A, Baskin H, Gokmen N, Yilmaz O, Genc K, Genc S, et al. Selective inhibition of nitric oxide in hypoxic-ischemic brain model in newborn rats: Is it an explanation for the protective role of erythropoietin?. Biol Neonate. 2004;85:51–54
  61. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med. 2003;198:971–975
  62. Mu D, Chang YS, Vexler ZS, Ferriero DM. Hypoxia-inducible factor 1alpha and erythropoietin upregulation with deferoxamine salvage after neonatal stroke. Exp Neurol. 2005;195:407–415
  63. Ohls RK, Ehrenkranz RA, Das A, Dusick AM, Yolton K, Romano E, et al. Neurodevelopmental outcome and growth at 18 to 22months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics. 2004;114:1287–1291
  64. Bierer R, Peceny MC, Hartenberger CH, Ohls RK. Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics. 2006;118:e635–e640
  65. Higgins RD, Raju TN, Perlman J, Azzopardi DV, Blackmon LR, Clark RH, et al. Hypothermia and perinatal asphyxia: executive summary of the national institute of child health and human development workshop. J Pediatr. 2006;148:170–175
  66. Dallman PR. Biochemical basis for the manifestations of iron deficiency. Annu Rev Nutr. 1986;6:13–40
  67. Lozoff B, Jimenez E, Hagen J, Mollen E, Wolf AW. Poorer behavioral and developmental outcome more than 10years after treatment for iron deficiency in infancy. Pediatrics. 2000;105:E51
  68. Buonocore G, Perrone S, Bracci R. Free radicals and brain damage in the newborn. Biol Neonate. 2001;79:180–186
  69. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood. 1991;78:2791–2808
  70. Drossou-Agakidou V, Kanakoudi-Tsakalidou F, Sarafidis K, Taparkou A, Tzimouli V, Tsandali H, et al. Administration of recombinant human granulocyte-colony stimulating factor to septic neonates induces neutrophilia and enhances the neutrophil respiratory burst and beta2 integrin expression. Results of a randomized controlled trial. Eur J Pediatr. 1998;157:583–588
  71. Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol. 1995;13:2547–2555
  72. Carlsson G, Ahlin A, Dahllof G, Elinder G, Henter JI, Palmblad J. Efficacy and safety of two different rg-csf preparations in the treatment of patients with severe congenital neutropenia. Br J Haematol. 2004;126:127–132
  73. Miura E, Procianoy RS, Bittar C, Miura CS, Miura MS, Mello C, et al. A randomized, double-masked, placebo-controlled trial of recombinant granulocyte colony-stimulating factor administration to preterm infants with the clinical diagnosis of early-onset sepsis. Pediatrics. 2001;107:30–35
  74. Carr R, Modi N, Dore C. G-CSF and GM-CSF for treating or preventing neonatal infections. Cochrane Database Syst Rev. 2003;[CD003066]
  75. Carr R, Modi N. Haemopoietic growth factors for neonates: assessing risks and benefits. Acta Paediatr Suppl. 2004;93:15–19
  76. Schabitz WR, Kollmar R, Schwaninger M, Juettler E, Bardutzky J, Scholzke MN, et al. Neuroprotective effect of granulocyte colony-stimulating factor after focal cerebral ischemia. Stroke. 2003;34:745–751
  77. Lee ST, Chu K, Jung KH, Ko SY, Kim EH, Sinn DI, et al. Granulocyte colony-stimulating factor enhances angiogenesis after focal cerebral ischemia. Brain Res. 2005;1058:120–128
  78. Solaroglu I, Cahill J, Jadhav V, Zhang JH. A novel neuroprotectant granulocyte-colony stimulating factor. Stroke. 2006;37:1123–1128
  79. Gibson CL, Jones NC, Prior MJ, Bath PM, Murphy SP. G-csf suppresses edema formation and reduces interleukin-1beta expression after cerebral ischemia in mice. J Neuropathol Exp Neurol. 2005;64:763–769
  80. Komine-Kobayashi M, Zhang N, Liu M, Tanaka R, Hara H, Osaka A, et al. Neuroprotective effect of recombinant human granulocyte colony-stimulating factor in transient focal ischemia of mice. J Cereb Blood Flow Metab. 2006;26:402–413
  81. Keller M, Simbruner G, Gorna A, Urbanek M, Tinhofer I, Griesmaier E, et al. Systemic application of granulocyte-colony stimulating factor and stem cell factor exacerbates excitotoxic brain injury in newborn mice. Pediatr Res. 2006;59:549–553
  82. Weber A, Dzietko M, Berns M, Felderhoff-Mueser U, Heinemann U, Maier RF, et al. Neuronal damage after moderate hypoxia and erythropoietin. Neurobiol Dis. 2005;20:594–600
  83. McPherson RJ, Demers EJ, Juul SE. Safety of high-dose recombinant erythropoietin in a neonatal rat model. Neonatology. 2007;91:36–43
  84. McClure MM, Threlkeld SW, Fitch RH. The effects of erythropoietin on auditory processing following neonatal hypoxic-ischemic injury. Brain Res. 2006;1087:190–195
  85. Spandou E, Papadopoulou Z, Soubasi V, Karkavelas G, Simeonidou C, Pazaiti A, et al. Erythropoietin prevents long-term sensorimotor deficits and brain injury following neonatal hypoxia-ischemia in rats. Brain Res. 2005;1045:22–30
  86. Wang CH, Liang CL, Huang LT, Liu JK, Hung PH, Sun A, et al. Single intravenous injection of naked plasmid DNA encoding erythropoietin provides neuroprotection in hypoxia-ischemia rats. Biochem Biophys Res Commun. 2004;314:1064–1071
  87. Kumral A, Gonenc S, Acikgoz O, Sonmez A, Genc K, Yilmaz O, et al. Erythropoietin increases glutathione peroxidase enzyme activity and decreases lipid peroxidation levels in hypoxic-ischemic brain injury in neonatal rats. Biol Neonate. 2005;87:15–18
  88. Kumral A, Uysal N, Tugyan K, Sonmez A, Yilmaz O, Gokmen N, et al. Erythropoietin improves long-term spatial memory deficits and brain injury following neonatal hypoxia-ischemia in rats. Behav Brain Res. 2004;153:77–86
  89. Kumral A, Ozer E, Yilmaz O, Akhisaroglu M, Gokmen N, Duman N, et al. Neuroprotective effect of erythropoietin on hypoxic-ischemic brain injury in neonatal rats. Biol Neonate. 2003;83:224–228
  90. Aydin A, Genc K, Akhisaroglu M, Yorukoglu K, Gokmen N, Gonullu E. Erythropoietin exerts neuroprotective effect in neonatal rat model of hypoxic-ischemic brain injury. Brain Dev. 2003;25:494–498

PII: S1744-165X(07)00016-9

doi: 10.1016/j.siny.2007.01.015

Seminars in Fetal & Neonatal Medicine
Volume 12, Issue 4 , Pages 250-258 , August 2007

Article Tools